Polygalacturonase gene FaPG1 downregulation is related to increased strawberry fruit resistance to fungal decay

Plant health is a major target in breading programs because crops are under constant biotic stress, and climate change is exacerbating pests and disease negative impacts in agriculture. Obtaining crop varieties armed with better defences is a potential strategy to reduce losses from biotic attacks. Plant cell walls perform crucial roles on many physiological processes, and under biotic stress, play crucial defensive roles as protecting barrier, as well as a source of integrity signalling molecules. Plant immunity has evolved a complex multi-layered system which first line of defence is initiated by conserved molecular patterns coming from pathogens, named pathogen-associated molecular patterns or PAMPs, or from their own corrupted cell walls due to pathogen invasion, named damaged-associated molecular patterns or DAMPs. Accumulating evidence from cell wall mutants has unveiled several components and mechanisms of plant innate immunity under biotic stresses, mostly in Arabidopsis, but still little is known from species with agronomic interest as strawberry. Our group has an established strawberry transgenic collection of cell wall mutants. Among them, RNAseq expression profiles of FaPG1 mutants has shown downregulation of other cell wall related genes than PG [1], but the mechanisms underneath required further investigation. FaPG genes code for enzymes with endo-PG activity related to oligogalacturonic acid (OGA) release, which would be associated to the changes in gene expression of other cell wall genes than FaPG. In this work, postharvest assays of FaPG1 fruits showed not only the increased fruit firmness typical of this mutant, but a better resistance to fungal infections by Botrytis cinerea, enhancing fruit shelf life in comparison with control fruits.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech

Efficient method for rapid multiplication of clean and healthy willow clones via in vitro propagation with broad genotype applicability

Willow is a versatile crop with considerable potential as a source of renewable biomass for bioenergy. Although breeding new varieties takes less time compared with some other tree species, producing new willow varieties is still a slow, labour-intensive process, partly because clonally propagating the results of each cross is a bottleneck early in the breeding scheme. In this paper, we describe a facile, rapid method for the in vitro culture of a wide range of willow genotypes. We have developed a combination of media and methods for efficient tissue-culture propagation to rapidly multiply individual plants and simultaneously produce clean, stock germplasm applicable to a wide range of willow genotypes that can be phytosanitary tested to demonstrate their disease-free status. The micropropagation method described could generate in the order of 5000 viable, transplantable clones from a single plant in just 24 weeks and was used to produce phytosanitary tested breeding material for export to overcome restriction on the international transport of woody cuttings. This method could represent a valuable biotechnology adjunct to willow breeding programmes and could accommodate early selection via molecular or biochemical markers

Guía docente común de las titulaciones de Ingeniero en Electrónica en las universidades andaluzas

El presente documento constituye el resultado del trabajo elaborado de acuerdo con la Convocatoria de Elaboración de Guías Docentes de Titulaciones Andaluzas conforme al Sistema de Créditos Europeos (años 2005/2006) de la Dirección General de Universidades, dependiente de la Secretaría General de Universidades, Investigación y Tecnología de la Consejería de Innovación, Ciencia y Empresa de la Junta de Andalucía

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

On Bayesian Forecasting of Procurement Delays: a Case Study

In the engineering and contracting sector, the on-time availability of materials is a crucial element of any project. In recent years, there has been increasing competition in the supply of such components, as a result of market globalization. This has generated customer demand for higher performance, service, and quality} and, most of all, shorter delivery times. However, it has also forced suppliers to increase efforts to satisfy these requirements in order to remain competitive. Thus, contractors have moved to focus their attention on the task of more precisely modelling on-time delivery risks. Historical data, expert opinion, and agreements between contractors and suppliers are some available sources of information that can be used to generate more accurate forecasts. We combine these various inputs in a Bayesian approach based on dynamic linear modelling. Our methodology has been implemented as a web-based Decision Support System, and has been applied in a real case study from an oil sector engineering and contracting company

Un modello dinamico lineare per la previsione dei tempi di approvvigionamento della componentistica

Forecasts of delivery times of components from subcontractors is becoming more and more important for engineering companies, which are required to build industrial plants not only at lower prices but also in shorter time than they used to do. We consider a Bayesian dynamic linear model, adapting a method, previously used in forecasting costs when bidding for industrial plants, in which external information, e.g. expert's opinion, is use